EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Anne-Marie Yvon on December 29, 2004.

The application has been amended as follows:

This listing of claims replaced all prior versions and listing of the claims:

1-65. (Cancelled)

66. (Currently amended) The complex according to claim 69 or 103, wherein the binding region has a K_D for the antibody of the first species of less than 10^{-6} M.

67. (Previously presented) The complex according to claim 66 in which the binding region has a K_D for the antibody of the first species of less than 10^{-8} M.

68. (Cancelled)

69. (Currently amended) A complex formed between (i) an antibody or biologically active fragment thereof from a first species and (ii) a bifunctional molecule, the bifunctional molecule comprising a binding region of non-antibody origin which binds to the antibody of the first species, and a constant region from an antibody of a second species, the constant region comprising at least one C_H domain or an epitope thereof, wherein the bifunctional molecule is bound to the constant region of the antibody of the first species, wherein ~~The complex according to claim 103, in which~~ the binding region [[is]] comprises a protein selected from the group consisting of[[,]] a mouse Fc γ receptor, histidine rich glycoprotein, *Streptococcal* protein G, *Staphylococcal aureus* protein A, [[and]] *Peptostreptococcus magnus* protein L, [[or a]] and antibody-binding fragments thereof.

70. (Previously presented) The complex according to claim 69, in which the binding region comprises fragment B of *Staphylococcus aureus* protein A.

71. (Currently amended) The complex according to claim [[103]] 69, in which the binding region comprises a mouse Fc γ receptor or fragment thereof.

4 ~~72.~~ (Currently amended) The complex according to claim [[103]] ~~69~~ 1, in which the binding region comprises histidine rich glycoprotein.

73-74. (Cancelled)

8 ~~75.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, wherein the constant region from the antibody of the second species comprises one or more constant domains from an IgM antibody.

9 ~~76.~~ (Previously presented) The complex according to claim ~~75~~ 8, in which the constant region from the antibody of the second species comprises one or more $C_H3\mu$ domains.

10 ~~77.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, wherein the constant region from the antibody of the second species comprises one or more constant domains from an IgG antibody.

11 ~~78.~~ (Previously presented) The complex according to claim ~~77~~ 10, in which the constant region from the antibody of the second species comprises one or more $C_H3\gamma$ domains.

12 ~~79.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, wherein the constant region from the antibody of the second species comprises one or more constant domains from an IgA antibody.

13 ~~80.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, wherein the constant region from the antibody of the second species comprises or consists of a non-naturally occurring combination of immunoglobulin C_H domains or epitopes thereof.

14 ~~81.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, in which the antibody constant region consists of a single C_H domain.

15 ~~82.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, in which the first species is a rat or mouse.

16 ~~83.~~ (Currently amended) The complex according to claim ~~69 or 103~~ 1 or 5, wherein the second species is a human.

84-102. (Cancelled)

5 ~~103.~~ (Currently amended) A complex formed between (i) an antibody or biologically active fragment thereof from a first species and (ii) a bifunctional molecule, the bifunctional molecule comprising a binding region of non-antibody origin which binds to ~~the antibody of the first species or to~~ one or more non-naturally occurring groups provided ~~thereon~~ on the antibody

of the first species, and a constant region from an antibody of a second species, the constant region comprising at least one C_H domain or an epitope thereof, wherein the bifunctional molecule is bound to ~~the constant region of the antibody of the first species or to~~ one or more non-naturally occurring groups provided ~~thereon~~ on the constant region of the antibody of the first species, wherein the non-naturally occurring group is a biotin molecule and the binding region comprises streptavidin or a fragment thereof.

17 ~~104~~. (Currently amended) The complex according to claim ~~69~~ 1 or ~~103~~ 15, wherein the binding region and the constant region from the antibody of the second species are linked directly or are separated by a linker molecule of between 1 and 20 amino acids in length.

105. (Cancelled)

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 10 a.m. to 9 p.m. M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571)272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karen A. Canella, Ph.D.
12/29/2004

Karen A. Canella
KAREN A. CANELLA PH.D
PRIMARY EXAMINER